CoChat

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Open access
Wattmo, Carina, Blennow, Kaj, Hansson, Oskar · 2020 · BMC Neurology

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

Background: We investigated the potential associations between cerebro-spinal fluid (CSF) levels of phosphorylated tau (P-tau) and total tau (T-tau) with short-term response to cholinesterase inhibitor (ChEI) treatment, longitudinal outcome and progression rates in Alzheimer’s disease (AD). Methods: This prospective, observational study included 129 participants clinically diagnosed with mild-to-moderate AD, who underwent a lumbar puncture. The CSF biomarkers amyloid-β 1–42 (Aβ 42), P-tau and T-tau were analysed with xMAP technology. Cognitive, global, instrumental and basic activities of daily living (ADL) capacities at the start of ChEI therapy and semi-annually over 3 years were evaluated. Results: All patients had abnormal Aβ 42 (A+). Fifty-eight individuals (45%) exhibited normal P-tau and T-tau (A+ T– (N)–), 12 (9%) abnormal P-tau/normal T-tau (A+ T+ (N)–), 17 (13%) normal P-tau/abnormal T-tau (A+ T– (N)+) and 42 (33%) abnormal P-tau and T-tau (A+ T+ (N)+). The participants with A+ T+ (N)+ were younger than A+ T– (N)+ at the estimated onset of AD and the initiation of ChEIs. The proportion of 6-month responders to ChEI and deterioration/year after start of treatment did not differ between the AT(N) profiles in any scales. A higher percentage of globally improved/unchanged patients was exhibited in the A+ T– (N)– group after 12, 30 and 36 months of ChEI therapy but not at other assessments. In apolipoprotein E (APOE) ε4-carriers, linear relationships were found between greater cognitive decline/year and higher tau; Mini-Mental State Examination score – T-tau (rs = − 0.257, p = 0.014) and Alzheimer’s Disease Assessment Scale–cognitive subscale – P-tau (rs = − 0.242, p = 0.022). A correlation between faster progression in instrumental ADL (IADL) and higher T-tau was also detected (rs = − 0.232, p = 0.028). These associations were not demonstrated in non-ε4-carriers. Conclusions: Younger age and faster global deterioration were observed in AD patients with pathologic tau and neurodegeneration, whereas more rapid cognitive and IADL decline were related to higher P-tau or T-tau in APOE ε4-carriers only. The results might indicate an association between more pronounced tau pathology/neuronal injury and the APOE ε4-allele leading to a worse prognosis. Our findings showed that the AT(N) biomarker profiles have limited utility to predict AD progression rates and, thus, measure change and interpreting outcomes from clinical trials of future therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12883-019-1591-0

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Cognitive status at baseline and CSF T-tau or P-tau by AT(N) biomarker profiles. a More impaired MMSE score at the start of ChEI therapy (time of AD diagnosis) showed a linear association with higher T-tau (rs = − 0.222, p = 0.012). b A negative correlation between the SATS patients’ MMSE score and P-tau (rs = − 0.204, p = 0.020) was also observed. c Worse ADAS-cog score at baseline demonstrated a linear relationship with higher T-tau (rs = 0.194, p = 0.030). Abbreviations: A+, abnormal CSF Aβ42; AD, Alzheimer’s disease; ADAS-cog, Alzheimer’s Disease Assessment Scale–cognitive subscale; ChEI, cholinesterase inhibitor; CSF, cerebro-spinal fluid; MMSE, Mini-Mental State Examination; (N)–, normal CSF T-tau; (N)+, abnormal CSF T-tau; P-tau, phosphorylated tau; SATS, Swedish Alzheimer Treatment Study; T–, normal CSF P-tau; T+, abnormal CSF P-tau; T-tau, total tau
Fig. 1 Cognitive status at baseline and CSF T-tau or P-tau by AT(N) biomarker profiles. a More impaired MMSE score at the start of ChEI therapy (time of AD diagnosis) showed a linear association with higher T-tau (rs = − 0.222, p = 0.012). b A negative correlation between the SATS patients’ MMSE score and P-tau (rs = − 0.204, p = 0.020) was also observed. c Worse ADAS-cog score at baseline demonstrated a linear relationship with higher T-tau (rs = 0.194, p = 0.030). Abbreviations: A+, abnormal CSF Aβ42; AD, Alzheimer’s disease; ADAS-cog, Alzheimer’s Disease Assessment Scale–cognitive subscale; ChEI, cholinesterase inhibitor; CSF, cerebro-spinal fluid; MMSE, Mini-Mental State Examination; (N)–, normal CSF T-tau; (N)+, abnormal CSF T-tau; P-tau, phosphorylated tau; SATS, Swedish Alzheimer Treatment Study; T–, normal CSF P-tau; T+, abnormal CSF P-tau; T-tau, total tauCC BY · PubMed Central
Fig. 2 Global response over 3 years of ChEI treatment. The proportion of improved/unchanged participants in global performance (CIBIC score, 1–4) from the initiation of ChEIs over 3 years according to AT(N) biomarker profile. A higher frequency of improved/unchanged patients was exhibited in A+ T– (N)– after 12 months (p = 0.034), 30 months (p = 0.005) and 36 months (p = 0.029) of therapy. No significant difference in AT(N) profiles was found between the improved vs. the unchanged individuals at any assessment. Abbreviations: A+, abnormal CSF Aβ42; ChEI, cholinesterase inhibitor; CIBIC, Clinician Interview-Based Impression of Change; CSF, cerebro-spinal fluid; (N)–, normal CSF T-tau; (N)+, abnormal CSF T-tau; T–, normal CSF P-tau; T+, abnormal CSF P-tau
Fig. 2 Global response over 3 years of ChEI treatment. The proportion of improved/unchanged participants in global performance (CIBIC score, 1–4) from the initiation of ChEIs over 3 years according to AT(N) biomarker profile. A higher frequency of improved/unchanged patients was exhibited in A+ T– (N)– after 12 months (p = 0.034), 30 months (p = 0.005) and 36 months (p = 0.029) of therapy. No significant difference in AT(N) profiles was found between the improved vs. the unchanged individuals at any assessment. Abbreviations: A+, abnormal CSF Aβ42; ChEI, cholinesterase inhibitor; CIBIC, Clinician Interview-Based Impression of Change; CSF, cerebro-spinal fluid; (N)–, normal CSF T-tau; (N)+, abnormal CSF T-tau; T–, normal CSF P-tau; T+, abnormal CSF P-tauCC BY · PubMed Central
Fig. 3 Cognitive and functional decline per year and CSF T-tau or P-tau in APOE ε4 carriers by AT(N) biomarker profiles. a More pronounced annual deterioration in MMSE score showed a linear association with higher T-tau at the start of ChEI therapy (time of AD diagnosis) (rs = − 0.257, p = 0.014). b Decline per year in ADAS-cog score demonstrated a negative correlation with P-tau at baseline (rs = − 0.242, p = 0.022). c A linear relationship between faster progression rate in IADL score/year and higher T-tau was also found (rs = − 0.232, p = 0.028). These correlations were not significant among the APOE non-ε4 carriers. Abbreviations: A+, abnormal CSF Aβ42; AD, Alzheimer’s disease; ADAS-cog, Alzheimer’s Disease Assessment Scale–cognitive subscale; APOE, apolipoprotein E; ChEI, cholinesterase inhibitor; CSF, cerebro-spinal fluid; IADL, Instrumental Activities of Daily Living Scale; MMSE, Mini-Mental State Examination; (N)–, normal CSF T-tau; (N)+, abnormal CSF T-tau; P-tau, phosphorylated tau; T–, normal CSF P-tau; T+, abnormal CSF P-tau; T-tau, total tau
Fig. 3 Cognitive and functional decline per year and CSF T-tau or P-tau in APOE ε4 carriers by AT(N) biomarker profiles. a More pronounced annual deterioration in MMSE score showed a linear association with higher T-tau at the start of ChEI therapy (time of AD diagnosis) (rs = − 0.257, p = 0.014). b Decline per year in ADAS-cog score demonstrated a negative correlation with P-tau at baseline (rs = − 0.242, p = 0.022). c A linear relationship between faster progression rate in IADL score/year and higher T-tau was also found (rs = − 0.232, p = 0.028). These correlations were not significant among the APOE non-ε4 carriers. Abbreviations: A+, abnormal CSF Aβ42; AD, Alzheimer’s disease; ADAS-cog, Alzheimer’s Disease Assessment Scale–cognitive subscale; APOE, apolipoprotein E; ChEI, cholinesterase inhibitor; CSF, cerebro-spinal fluid; IADL, Instrumental Activities of Daily Living Scale; MMSE, Mini-Mental State Examination; (N)–, normal CSF T-tau; (N)+, abnormal CSF T-tau; P-tau, phosphorylated tau; T–, normal CSF P-tau; T+, abnormal CSF P-tau; T-tau, total tauCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 102

Metadata

Authors
Wattmo, C., Blennow, K., & Hansson, O.
Affiliations
  • Lund University (SE)
  • University of Gothenburg (SE)
Corresponding author
Wattmo, Carina
Venue
BMC Neurology
Published
2020-01-09
Volume
20
Issue
1
Pages
10-10
ISSN
1471-2377 (ISSN-L)
OpenAlex
W2999996692
Cited by
93
References
59
Citations by year
2026: 11 · 2025: 17 · 2024: 12 · 2023: 16 · 2022: 21 · 2021: 12 · 2020: 4
FWCI
9.66
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Neurology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Hjärnfonden (na)
  • Greta och Johan Kocks stiftelser (na)
  • Skånes universitetssjukhus (na)
  • Demensförbundet (na)
  • Torsten Söderbergs Stiftelse (na)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, cerebrospinal fluid biomarkers, phosphorylated tau, total tau, amyloid-beta 42, cholinesterase inhibitors, treatment response, disease progression, cognitive decline, activities of daily living, biomarker profiles, longitudinal outcomes, mild to moderate Alzheimer's disease
MeSH terms
Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Cholinesterase Inhibitors, Female, Genotype, Humans, Male, Phosphorylation, Prospective Studies, Biomarkers, tau Proteins, Disease Progression, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s12883-019-1591-0
The paper
Wattmo, C., Blennow, K., & Hansson, O. (2020). Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease. BMC Neurology. https://doi.org/10.1186/s12883-019-1591-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.